Pretargeting: Improved Pharmacokinetics and Therapeutic Ratio

Pre-clinical studies of three step pretargeting of an anti-hapten mAb were done in BALB/c mice with KHJJ mouse adenocarcinoma. An 80% reduction in whole body radiation burden and a 10 fold increase in Therapeutic Ratio was achieved, compared to directly labeled mAb in this model.